van Rooijen & Partners is proud to present the business deal between Morphochem, Migragen and Schering. <<
Press release.
Morphochem/Migragen collaboration sells Rho-kinase patent to Schering AG
Munich and Tuebingen, Germany, September 20, 2004.
Morphochem AG and the representatives for Migragen i.L. today announced that all rights from Morphochem and Migragen i.L. to a patent application covering novel Rho-kinase inhibitors and their applications have been sold to Schering AG, Germany (FSE: SCH, NYSE: SHR). The patent application also covers new uses for known compounds that were discovered using Morphochem’s technologies.
Financial terms of the collaboration were not disclosed.
About Morphochem AG (www.morphochem.de):
Morphochem was founded in 1998 and currently employs 45 staff in Munich, Germany and Basel, Switzerland. It has developed a unique and highly integrated chemical genomics drug discovery platform that it is applying to the development of a pipeline of drugs for unmet medical needs in major areas of indications such as thrombosis and infectious diseases as well as partnering its technology with others. Morphochem has raised €84.7 million from a world class syndicate of investors including Techno Venture Management (TVM), Alta Berkeley, Alta California, Life Science Partners, Merlin Biosciences, Nomura International, West LB Panmure, 3i Bioscience Investment Trust, 3i Group, Domain Associates, Mayfield Fund, Viscardi, IKB Venture Capital, Süd VC, KB Lux, Bank Julius Bär, Bionex Investments, and others including federal and state government sources.
About Migragen:
Migragen AG was a venture backed biopharmaceutical company in Tuebingen, Germany, which filed for insolvency last year. The company perspektiv GmbH, Munich, Germany (www.perspektiv.de) has been assigned by the administrator, Gerhard Walter, Tuebingen, Germany, to commercialise the assets and was consulted by Dr. Lucio A.A. van Rooijen at van Rooijen & Partners (www.vr-p.com).
Migragen had focused on various facets of the Rho pathway, primarily in relation to spinal cord injury and other CNS diseases related to re- and degeneration. The assets include various patents by Migragen and with Morphochem, Garching Innovation at the Max Planck Institute and Yale University.
For further information, please contact:
At Morphochem:
Dr Peter Seufer Wasserthal
VP Business Development
Phone: +43-7673-321-511
E-mail: peter.seufer@morphochem.de
For Migragen:
van Rooijen & Partners
Dr. Lucio A.A. van Rooijen
Phone: +49-8847-6997-26
E-Mail: LvR@vr-p.com